Although small deletions, splice site abnormalities, mismutation disrupts the binding of HNF-4 to its cognate binding site. In growth hormone reporter gene assays, the activsense, and nonsense mutations have been identified in patients with factor VII deficiency, there have been no reports ity of a plasmid containing the mutant promoter was 6.7% of the wild-type promoter plasmid. Although HNF-4 was able of mutations in the factor VII promoter. We investigated a girl with factor VII levels that were less than 1% of normal to transactivate the wild-type factor VII promoter 5.4-fold in HeLa cells, no transactivation could be shown with the muin association with a severe bleeding diathesis. The patient is homozygous for a T to G transversion that occurs 61 bp tant promoter. These findings indicate that HNF-4 exerts a major positive regulatory effect on factor VII expression and before the translation start site. This nucleotide is in a sequence that is an hepatocyte nuclear factor 4 (HNF-4) bindprovides in vivo evidence that binding of this transcription factor is critical for normal factor VII expression. ing site within the factor VII promoter (ACTTTG AE r ACGTTG). Using gel mobility shift assays, we show that the ᭧ 1997 by The American Society of Hematology.
11, 12 The major transcription start site for factor VII is located approximately 50 bp upstream from the first base of UMAN FACTOR VII is a vitamin K-dependent glycoprotein that circulates in blood as an inactive zymogen. It plays a critical role in the initiation of coagulation the codon for the initiation methionine (/1) and is in close proximity to the binding sites of transcription factors Sp1 by binding to tissue factor, which is exposed on vascular injury. This interaction enables factor VII to be rapidly actiand hepatocyte nuclear factor 4 (HNF-4), which bind at sites that include nucleotides 0100 to 094 and 063 to 058 vated to factor VIIa; the factor VIIa-tissue factor complex then initiates blood coagulation by activating factor IX as (ACTTTG), respectively.
9,10
We have investigated the molecular mechanism underlywell as factor X.
1,2
The human factor VII gene is located on chromosome ing factor VII deficiency in a young girl with a severe bleeding diathesis who is homozygous for a T to G transversion 13q34, 3 2.8 kb upstream from the coagulation factor X gene. 4 It contains 9 exons separated by 8 introns and the entire at nucleotide 061 (ACGTTG) in the factor VII promoter. Our data show that this mutation disrupts HNF-4 binding sequence spans about 12.8 kb.
5 During the last 5 years, more than 20 different mutations have been described in patients and results in a significant reduction in factor VII promoter activity. with factor VII deficiency. 6 Most have been missense mutations, but nonsense mutations, small deletions, and splice
MATERIALS AND METHODS
site abnormalities have also been identified. 7 
Several groups have recently identified and characterized
Clinical history. The proband is a 6-year-old American girl with a severe bleeding diathesis caused by factor VII deficiency. Her essential regulatory elements in the 5-flanking region of the parents are of French Canadian ancestry, and there is no familial factor VII gene. [8] [9] [10] Unlike many eukaryotic promoters, it history of bleeding or known consanguinity. She was noted to have lacks TATA and CAAT boxes. The absence of a CAAT box blood in her stools at about 2 months of age and bruising with contrasts with the promoter structure of factor IX and factor minimal trauma at 4 months. At 8 months, she presented with a X, two closely related vitamin K-dependent coagulation prospontaneous cerebral hemorrhage in the right frontal lobe which teins in which a CAAT box is critical for promoter activ- 14 The inserts were sequenced by the dideoxy chain termination method 15 Madison, WI) used as an internal control for transfection efficiency, were introduced into cells by LipofectAmine transfection. After 12 on an Applied Biosystems 373A DNA Sequencer (Foster City, CA). Four to six independent clones containing the sequence of each exon hours, medium was changed, and 48 hours later, the supernatants and cell lysates were procured and assayed for growth hormone were analyzed.
Allele specific PCR (ASPCR). Primer-directed allele specific amand b-galactosidase activity, respectively. Results of transient assays performed in HepG2 cells are expressed in ng/mL of growth horplification 16 with minor modifications 14 was used to detect a single base substitution in the 5-flanking region of the factor VII gene. mone and represent the average { 1 SD obtained in six independent transfections. Transactivation experiments in HeLa cells were perTo this end, sense oligonucleotides of 14 bp containing the mutant (5-GGAGGCAGAGAACG) or normal base (5-GGAGGCAGAformed with 5 mg of the GH reporter gene construct, 10 mg of the HNF-4 expression plasmid pLEN4S 18 or pLEN basic vector, and 2 GAACT) were used with a common antisense primer (5-ACCAAG-TTTATGGAGAAAAC) to amplify a 170 bp fragment from the mg of the internal control plasmid pSV-b-galactosidase. The plasmid pLEN4S (a gift from Dr James E. Darnell Jr, Rockefeller University, mutant or normal allele, respectively. PCR reactions were performed in a total volume of 20 mL containing 0.3 mmol/L of each oligonucleNew York, NY) contains the entire 3-kb HNF-4 cDNA cloned into pLEN, a 5-kb expression plasmid containing the SV40 enhancer, otide, 0.01 pmol of template (a PCR fragment spanning from base pair 0416 to /98), 0.4 U of Taq DNA polymerase, 70 mmol/L of metallothionein promoter, and the human growth hormone gene 3-untranslated region. Results are expressed in ng/mL of growth horeach dNTP, and 1.0 mmol/L of MgCl 2 . Optimal annealing temperatures for each set of primers were previously determined and amplimone and represent the average { 1 SD obtained in three independent transfections. fications were performed for 28 cycles. After completion of the ASPCR, 5 mL of the reaction mixture were subjected to electrophoreHuman growth hormone and b-galactosidase assays. Aliquots of medium from transfected HepG2 or HeLa cells were assayed for sis in a 1.5% (wt/vol) agarose gel containing 0.5 mg/mL ethidium bromide and photographed under UV transillumination.
growth hormone using a radioimmunoassay (Nichols Diagnostics Institute). Growth hormone levels were calculated from a standard Detection of polymorphic alleles containing the decanucleotide insert at 0323. Approximately 200 ng of a 514 bp PCR fragment curve that was fitted using a four parameter logistic model. b-Galactosidase activity in cell lysates was assayed colorimetrically at 419 containing a portion of the 5-flanking region of the factor VII gene were digested with 10 U of EcoRI (New England Biolabs, Beverly, nm at 37ЊC using a commercially available kit (Promega Corp). The samples were placed in microtiter plates and read by a plate reader MA). Electrophoresis was performed in a nondenaturing polyacrylamide gel (8% wt/vol). The gel was stained in 0.5 mg/mL ethidium (Molecular Devices, Menlo Park, CA) in the kinetic mode over a 1 hour period. b-Galactosidase values were obtained from a standard bromide for 5 minutes and photographed under UV transillumination. Cleavage at an EcoRI restriction site at position 0313 in the curve that had been fitted by linear regression using the least-squares method. Growth hormone concentrations were normalized with re-PCR fragment results in products of 421 and 93 bp, or 421 and 103 bp if the decanucleotide insert is present.
spect to b-galactosidase activity to correct for differences in transfection efficiency between plates. To account for background growth Detection of polymorphic alleles containing Arg 353 Gln. Msp I restriction enzyme analysis was performed to show the presence of hormone activity, parallel transfections with the promoterless vector pOGH were performed. Growth hormone levels were then normalArg 353 Gln.
14 Construction of growth hormone reporter gene plasmids. The ized to b-galactosidase activity as described above, and were subtracted from the values obtained for each individual transfection promoterless plasmid pOGH (Nichols Diagnostics Institute, San Juan Capistrano, CA) containing the structural human growth hormone experiment. Preparation of human liver nuclear extracts. Human liver was gene was used for reporter gene plasmid constructs. 17 The construction of the plasmid p186GH with nucleotides 0185 to /1 of the obtained from discarded liver transplant specimens under a protocol approved by the Institutional Review Board at the Children's Hospihuman factor VII gene inserted into plasmid pOGH has been described in detail. 10 To generate a plasmid containing the T to G tal of Philadelphia. The method described by Gorski et al 19 was used to prepare human liver nuclear extracts. Aliquots of 200 mL were substitution at position 061 of the factor VII promoter, 5 we amplified a 214 bp fragment spanning the mutation site by PCR using genomic frozen in liquid nitrogen at 0196ЊC until use. Protein concentration was determined using the method described by Bradford et al. 20 DNA from the proband as template. HindIII and BamHI restriction sites were artificially introduced at the 5 and 3 ends of the fragment, Gel mobility shift assays. The gel mobility shift assay was performed using the method described by Chodosh et al 21 with minor respectively. Restriction digests with these enzymes yielded a 186 bp fragment, which was gel purified and substituted for the homolomodifications. Complementary oligonucleotides of 30 bp (from nucleotide 076 to 047, 5 to the factor VII translation start site) gous wild-type fragment in p186GH. The new plasmid containing the mutation, p186GHm, was sequenced to exclude the presence of spanning the HNF-4 binding site in the human factor VII promoter were annealed and end-labeled using [g0 32 P]ATP and 10 U T4 other base substitutions that might have been introduced during PCR amplification. All plasmids were purified using DNA purification polynucleotide kinase at 37ЊC for 30 minutes. The radiolabeled oligonucleotide was purified with a Sephadex G-50 quick spin column columns (Qiagen Inc, Chatsworth, CA), resuspended in 10 mmol/L Tris pH 8.5 (25ЊC), and stored at 080ЊC until use. Gln in exon 8 22 and a decanucleotide insert at position 0323 in the 5-flanking region of the factor VII gene. 23 Neither the patient nor her mother had these polymorphisms. The patient's father, who had a VII:C level that was 33% after, DNA-protein mixtures were electrophoresed and autoradiolower than his wife, was heterozygous for both polymor- in Italy 24 and the UK 25 show strong allelic association between Arg 353 Gln and the decanucleotide insert.
RESULTS

Transient transfection assays in HepG2 cells. To invesCoagulation studies.
The patient is a 6-year-old girl with tigate whether the T to G substitution at position 061 influa severe bleeding diathesis due to factor VII deficiency. She enced factor VII promoter activity, we analyzed the activity had a prothrombin time that was markedly prolonged at 28.6 of the wild-type (p186GH) and mutant promoters seconds (normal range 10.0 to 13.0 seconds) and a normal (p186GHm) in transiently transfected HepG2 cells. To conactivated partial thromboplastin time. Her levels of VII:C trol for transfection efficiency, a b-galactosidase plasmid and VII:Ag were both less than 1% of normal, while those was cotransfected along with the growth hormone reporter in her father and mother were 33% and 30% and 44% and gene constructs and the results were normalized with respect 38%, respectively (Table 1) .
to b-galactosidase expression. In six independent transfecGenomic studies. Sequencing of subcloned PCR fragtions with each construct, the mean activity of the mutant ments containing 149 bp of the 5-flanking region demonplasmid in directing growth hormone transcription was 6.7 strated a T to G substitution at nucleotide 061 of the factor { 3.8 (1 SD) percent of the wild-type plasmid (0.22 { 0.13 VII gene (data not shown). This abnormality was identified ng/mL v 3.34 { 0.36 ng/mL, Fig 2) . Transfection with the in each of six independent clones, and no sequence alterpromoterless vector pOGH yielded a growth hormone level ations were identified in any of the exons of the factor VII in the media of 0.20 { 0.06 ng/mL. gene.
Gel mobility shift assay. A gel mobility shift assay using To demonstrate homozygosity definitively, we tested for a 30 bp oligonucleotide spanning a previously shown HNFthe presence of the T to G substitution at nucleotide 061 4 binding site in the human factor VII promoter 10 was used to show that the 061 T to G mutation prevented HNF-4 in the patient and her parents using ASPCR because the , 3) demonstrating the specificity of the probe for this protein, previously identified to be HNF-4. [8] [9] [10] The faint signal in lane 3, which contains a 500-fold excess of unlabeled competitor, results from the long exposure of the gel and was not seen with more typical exposure times. 10 The mutant factor VII promoter sequence, containing the transversion at 061 present in the propositus, did not compete away HNF-4 binding (lanes 4 and 5) . The mutant sequence did not bind any liver nuclear extract protein (lanes 6 through 10); no signal was detected even after prolonged exposure of the gel.
Transactivation studies in HeLa cells. To provide further evidence that defective binding of HNF-4 to the mutant factor VII promoter is responsible for its reduced transcriptional activity, we performed transactivation studies in a nonhepatocyte cell line which does not constitutively support factor VII promoter activity. 10 To this end, the expression vector pLEN4S that codes for HNF-4 or the empty pLEN the factor VII promoter.
The higher growth hormone levels in HeLa cells (Fig  4) as compared to HepG2 cells (Fig 2) are attributable to binding to the human factor VII promoter. To accomplish differences in transfection efficiencies and experimental conthis, the gel was exposed to film for a time interval that was ditions. Before normalizing data with respect to b-galactosiapproximately three times as long as usual. The wild-type dase activity, the activities of the wild-type and mutant prooligonucleotide bound a protein present in human liver nuclear extract (Fig 3, lane 1) . Unlabeled wild-type sequence moters in directing growth hormone transcription in HepG2 10 The identity of the liver-enriched transcription factor HNF-4 as the protein that binds at nucleotides 063 to 058 was established by ''supershift'' experiments with a specific antibody to HNF-4, [8] [9] [10] by competition experiments with the oligonucleotide from the apolipoprotein CIII promoter that was originally used as an affinity ligand to purify HNF-4 from nuclear extracts, 9,10 and by experiments using in vitro transcribed and translated HNF-4. 29 The functional significance of the Sp1 and HNF-4 binding sites was shown in mutagenesis experiments, which showed dramatically reduced promoter activity when the nucleotide sequence of the binding sites was disrupted. fold, while no effect was seen with the mutant promoter.
HNF-4 transactivates the wild-type factor VII promoter 5.4-fold in a nonhepatic environment, no transactivation can be shown with the mutated promoter. Taken together, these cells (2.21 { 0.30 ng/mL and 0.39 { 0.05 ng/mL, respecfindings suggest that disruption of the HNF-4 binding site tively) were actually similar to those in HeLa cells that had is sufficient to cause the patient's severe factor VII defibeen cotransfected with the HNF-4 expression vector (2.63 ciency. The patient's severe clinical phenotype supports the { 0.23 ng/mL and 0.58 { 0.04 ng/mL, respectively).
in vitro finding that HNF-4 exerts a major positive regulatory effect on factor VII expression and provides in vivo evidence DISCUSSION that binding of this transcription factor is critical for normal factor VII expression. Factor VII deficiency, an autosomal recessive disorder, It is of interest that Greenberg et al 9 mutated position 060 occurs with an estimated incidence of 1 per 500,000 in the (ACTTTG AE r ACTCTG) and position 059 (ACTTTG AE general population. Afflicted patients exhibit a highly varir ACTTCG) in the factor VII promoter and observed deable hemorrhagic predisposition, and the correlation between creases in promoter activity to 17% and 22% of wild-type, bleeding tendency and plasma level of factor VII activity is respectively. Our in vitro data showing that a mutation at often discordant. 26, 27 Patients with levels of less than 1% can 061 causes a greater than 93% reduction in factor VII proexperience severe bleeding episodes including hemarthroses moter activity might suggest that this nucleotide is more and intracranial hemorrhage. The propositus of this study critical than 060 or 059 in HNF-4 binding. Definitive conwas severely affected and sustained life-threatening bleeds clusions regarding the relative importance of these nucleothat eventually required maintenance therapy with factor VII concentrate. We found that the propositus was homozygous for a T to G transversion at nucleotide 061, which is the first instance of factor VII deficiency caused by a promoter mutation. It is likely that her parents share a common ancestor who carried this genetic defect.
The factor VII promoter has only recently been analyzed in detail. [8] [9] [10] The major transcription start site has been reported within a strong initiator element (057 CCCGTC-AGTCCC 046) 28 at position 051 10 and 050 9 upstream from the start site of translation (/1), in close proximity to the mutation reported here. Analysis of promoter activity using varying lengths of 5-flanking sequence adjacent to the translation start site in reporter gene assays demonstrated that 36, 37 nucleotide substitutions at 060 and 059 in the same construct that was used to test the 061 mutation, which has not Because it is unclear why male children with hemophilia B Leyden exhibit an increase in clotting factor expression been done here.
Current models of transcription suggest that the complete following puberty, it is impossible to predict whether our female patient with factor VII deficiency, who also has a set of general transcription factors (RNA polymerase II and TFIIA-TFIIH) are sufficient to direct basal transcription from mutation at the HNF-4 binding site, will have an increase in factor VII expression after puberty. The site containing strong promoters such as those containing TATA boxes. 28 However, studies involving transcriptional activation in the mutation (AGAACGTTGCCCGTC) exhibits strong homology to the ARE (AGNACANNNTGTNCT) at its 5 end TATA-less promoters suggest the importance of direct interactions between general transcription factors and site-spe-(8 of 9 nucleotides match), but little homology at its 3 end (1 of 9 nucleotides match). The 061 T to G mutation changes cific accessory transcription factors that serve as activators. In the context of the apoAI promoter, HNF-4 was recently a pyrimidine to a purine, which results in a closer match with the ARE than the wild-type sequence. Interestingly, shown to facilitate the formation of the preinitiation complex of transcription through a direct contact with TFIIB, 30 a gencarriers of mutations that result in Hemophilia B Leyden have not been shown to exhibit the same postpubertal ineral transcription factor which, in association with RNA polymerase II, facilitates promoter recognition and accurate crease in factor IX levels exhibited by affected patients. 38 Thus the fact that the parents of the propositus in this report transcription initiation. 28 In the factor VII promoter, the presence of an HNF-4 binding site several bases upstream of the have subnormal levels of factor VII does not necessarily imply that their child will not experience a developmental transcription start site coupled with the evidence from this study that severe factor VII deficiency results from a mutarise in her factor VII levels. tion that disrupts HNF-4 binding, suggest that HNF-4 does ACKNOWLEDGMENT act as an activator in the TATA-less factor VII promoter. Furthermore, an ACTTTG motif, conserved within the factor
